Author Archive for: ERA-EDTA
Entries by ERA-EDTA
The risks of gastrointestinal adverse events with initiation of sodium polystyrene sulphonate
Sodium polystyrene sulphonate (SPS) has been widely used for hyperkalemia management in chronic kidney disease (CKD). However, data on its safety are scarce and ambiguous. A retrospective cohort study based on the nationwide Swedish Renal Registry examined patterns of use and adverse events associated to SPS initiation during follow-up. 3690 patients initiated SPS during follow-up, […]
Are all donated kidneys the same?
The increase in kidney transplant activity in Spain in recent years has relied on acceptance of organs from increasingly older donors and donation after circulatory death (cDCD). This has triggered Concerns about outcomes achieved with these elderly cDCD. A single-ceter retrospective study evaluated 87 cDCD-kidney transplant recepients (KTrs), 46 from donors ≥65 years of age and […]
Which phosphate transporters should be targeted to reduce hyperphosphatemia?
NaPi-IIb, a type II sodium-dependent phosphate transporter, is considered a dominant transporter in rodents for phosphate absorption in the small intestine. However, the regulation of its expression in chronic kidney disease (CKD) is still ambiguous. A recent study measured protein expression level of NaPi-Iib in CKD-rats by mass spectrometry to evaluate the extent of phosphate […]
Does ADH modulate renal calcium excretion in patients with CDI and hypercalciuria?
Antidiuertic hormone (ADH), commonly known for regulating body’s water balance, has recently been linked to osteoporosis during ageing and microgravity/bed rest. This prompted a research on the possible role od ADH in modulating renal calcium excretion. Data for 12 patients with central diabetes insipidus (CDI) and measured 24-h urinary excretion levels of calcium have been […]
Tolvaptan maintains diuretic action in hemodialysis patients
Tolvaptan is an oral aquaretic agent which selectively antagonizes arginine vasopressin V2 receptors and increases free water excretion. A total of 124 hemodialyzed patients with preserved diuresis were recruited in a randomized, double-blind, placebo-controlled, Phase 2 trial to assess tolvaptan efficacy and safety. They were randomized to receive oral tolvaptan 15 mg/day or 30 mg/day, or placebo […]
PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab treatment
Rituximab (RTX) is an effective remission-induction and maintenance treatment for patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The major challenge of patient care is the early detection of relapse to prevent organ damage and improve survival in these individuals. A recently published single-center cohort study assessed serial ANCA, CD19+ B-cell status and relapse rate […]
Acute PD in the treatment of COVID-19-related AKI
Acute kidney injury (AKI) may occur in 4-23% of patients with COVID-19. Those who require renal replacement therapy have mainly been treated with extracorporeal dialysis. However, peritoneal dialysis (PD) may also be considered as a valuable treatment option in such cases when there is a capacity limit or availability constraint of equipment and supplies for […]
ERA-EDTA Operative Headquarters
Strada dei Mercati 16/A
I-43126 Parma – Italy
Phone: +39 0521 989078
E-mail: secretariat@era-edta.org
ERA-EDTA Registered Office
c/o PKF Littlejohn, 15 Westferry Circus, Canary Wharf
London E14 4HD – United Kingdom